188 related articles for article (PubMed ID: 21885241)
1. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
Rasti M; Blostein M
Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
[TBL] [Abstract][Full Text] [Related]
2. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
Nguyen N; Salib H; Mascarenhas DA
J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
5. Readministration of abciximab in percutaneous coronary intervention.
Fry ET
J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
[TBL] [Abstract][Full Text] [Related]
6. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Dorsch MP; Montague D; Rodgers JE; Patterson C
Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
[TBL] [Abstract][Full Text] [Related]
8. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
9. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
10. Acute profound thrombocytopenia following abciximab therapy.
Bishara AI; Hagmeyer KO
Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
[TBL] [Abstract][Full Text] [Related]
11. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
Elmi F; Oza R; Mascarenhas DA
J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
13. Abciximab readministration.
Orford JL; Holmes DR
Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia associated with c7E3 Fab (abciximab).
Schell DA; Ganti AK; Levitt R; Potti A
Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
[TBL] [Abstract][Full Text] [Related]
15. Abciximab-induced delayed profound thrombocytopaenia.
Jbara M; Bhogal S; Bajaj K; Chhabra L
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576909
[TBL] [Abstract][Full Text] [Related]
16. Reversal of recurrent thrombocytopenia due to abciximab.
Sharma V; Mascarenhas D
J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
[No Abstract] [Full Text] [Related]
17. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
18. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
19. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro.
Kozak M; Dovc T; Rozman P; Blinc A
Wien Klin Wochenschr; 2000 Feb; 112(3):138-41. PubMed ID: 10729966
[TBL] [Abstract][Full Text] [Related]
20. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
Goldschmidt-Clermont PJ
J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
